PEAK6’s Altimmune ALT Stock Holding History

PEAK6’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3,423	Closed	-$13.2K	–	2896
2025 Q2	$13.2K	Buy	+3,423	New	+$18.5K	﹤0.01%	2771
2025 Q1	–	Sell	-61,948	Closed	-$447K	–	2949
2024 Q4	$447K	Buy	+61,948	New	+$473K	﹤0.01%	2209

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

PEAK6's ALT Position: Q3 2025 in Review

PEAK6 sold out of Altimmune (ALT) in Q3 2025, closing a stake of 3,423 shares — an estimated $13.2K sold.

PEAK6 first reported a position in ALT in Q4 2024 and held it in 2 quarters. The position peaked at $447K in Q4 2024. 158 funds tracked by Wall St. Rank hold ALT as of Q3 2025.

PEAK6 reported no remaining Altimmune position as of Q3 2025 after selling out during the quarter.
PEAK6 sold 3,423 Altimmune shares in Q3 2025, an estimated $13.2K.
PEAK6 first reported a position in Altimmune in Q4 2024 and held it in 2 quarters.
PEAK6's Altimmune position peaked at $447K in Q4 2024.
158 funds tracked by Wall St. Rank held Altimmune as of Q3 2025.

Based on PEAK6's 13F filing for Q3 2025, filed 14 Nov 2025.